1. Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati)
- Author
-
Anna Paioli, Alessandro Parra, Alberto Righi, Luca Morandi, Stefano Ferrari, Elisabetta Setola, Lorenzo D'Ambrosio, Giovanni Grignani, Rossella Hakim, Massimo Eraldo Abate, Franca Fagioli, Marilena Cesari, Katia Scotlandi, Asaftei Dorin Sebastian, Davide Maria Donati, Alessandra Longhi, Michela Pasello, Maria Cristina Manara, Robin L. Jones, Emanuela Palmerini, Palmerini, Emanuela, Pasello, Michela, Jones, Robin Lewi, Manara, Maria Cristina, Fagioli, Franca, Grignani, Giovanni, Longhi, Alessandra, Cesari, Marilena, Abate, Massimo Eraldo, Paioli, Anna, Setola, Elisabetta, Hakim, Rossella, D'Ambrosio, Lorenzo, Parra, Alessandro, Sebastian, Asaftei Dorin, Righi, Alberto, Morandi, Luca, Donati, Davide Maria, Ferrari, Stefano, and Scotlandi, Katia
- Subjects
Cancer Research ,Temozolomide ,O6-methylguanine ,Abcg2 ,biology ,business.industry ,medicine.disease ,DNA methyltransferase ,Irinotecan ,Oncology ,medicine ,Recurrent Ewing Sarcoma ,Cancer research ,biology.protein ,Sarcoma ,business ,neoplasms ,Ewing sarcoma ,medicine.drug - Abstract
e23564 Background: Activity of temozolomide (TEM) and irinotecan (IRI) in recurrent Ewing sarcoma (EWS) was demonstrated. Few data are available on TEMIRI use upfront. Biological predictive factors are lacking. Methods: This multi-institutional retrospective study (NCT03542097) included 59 patients with EWS. 8 patients with very high risk (HR) EWS (multivisceral ± bone marrow) received TEMIRI (TEM 100 mg/m2/day oral, and IRI 40 mg/m2/day intravenous, days 1-5, every 21 days) upfront, 51 patients after relapse (28% in 1st line, 72% ≥ 2nd line). Overall response rate (ORR: CR+PR), SD, and PD, progression-free (PFS) and overall survival (OS) were assessed. The relationship between pre-treatment expression of MGMT and ABCG2 (when FFPE tissue available) with ORR, PFS and OS was evaluated. Results: Median age was 27 years (range 4-62 years): 47 patients (80%) were adults (≥18 years), 35 (61%) had ECOG 0 and 42 (71%) presented with multivisceral disease (+ bone marrow in 5). MGMT was positive in 16/30 (53%), ABCG2 in 4/33 (12%). ORR for upfront TEMIRI (n = 8) was 50% (CR + PR = 1 + 3), with SD 50%, while in recurrent EWS (n = 49, 2 patients no measurable by RECIST) ORR was 31% (CR + PR = 4 + 11), SD 38%, and PD 31%. A better ORR was observed in adult (p = 0.008) & ECOG 0 (p = 0.001) patients; MGMT & ABCG2 expression did not influence ORR. 6-mos PFS was 87% after TEMIRI upfront, 43% at recurrence (p = 0.06), and 65% vs 28% (p = 0.02) for ECOG 0 vs ECOG 1-2, respectively. 6-mos PFS was 62% in MGMT+ vs 33% in MGMT- (p = 0.4) and 75% in ABCG2+ vs 50% in ABCG2- (p = 0.7). Median time to progression (TTP) with upfront TEMIRI was 9 months (range 5-28 months), with 1 patient with ongoing CR at 56 months; median TTP at relapse was 3 months (1-29 months). MGMT and ABCG2 expression did not influence 1-yr OS, whereas ECOG (0 vs 1-2) did (88% vs 31% p < 0.001). Grade 3-4 diarrhea, neutropenia, and thrombocytopenia incidence was < 5%, 1 patient with recurrent kidney EWS died of acute liver failure. Conclusions: TEMIRI showed promising activity in a very unfavorable cohort of EWS patients, with manageable toxicity. Performance status correlated with 6-month PFS & OS whereas MGMT & ABCG2 did not. Clinical trial information: NCT03542097 .
- Published
- 2020